GlassScriptPhysician profile
Amy Valentine
NPI 1922546589
$4,914.11
in general payments reported to CMS, 2019-2025
22 companies · $984 in 2025
The $984 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $1,234 · 2023: $837 · 2024: $1,351 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.59 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,239.85 | 2021-2025 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $1,165.57 | 2021-2025 | |
| Boston Scientific Corporation | $610.56 | 2022-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.47 | 2021-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.56 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $167.99 | 2021-2025 | Verquvo |
| Amgen INC. | $139.61 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $111.08 | 2021-2023 | Farxiga, Brilinta |
| Abiomed | $99.06 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $93.74 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $74.99 | 2022 | |
| Shockwave Medical, INC | $67.27 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $58.27 | 2023-2024 | Evkeeza |
| Janssen Pharmaceuticals, INC | $56.35 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $43.38 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $36.78 | 2025 | Nexletol |
| Pfizer INC. | $34.20 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $30.19 | 2025 | Amvuttra |
| Silk Road Medical, INC. | $26.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2025 | |
| Scpharmaceuticals INC. | $15.14 | 2024 | |
| Inspire Medical Systems, INC. | $15.06 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Valentine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.